Abstract
In this issue of Blood, 2 companion articles by Flinn et al1 and Horwitz et al2 present promising phase 1 data demonstrating clinical efficacy of the dual inhibitor of phosphatidylinositol 3-kinase (PI3K)-d and PI3K-g duvelisib in patients with advanced hematologic malignancies, including T-cell lymphomas (TCLs).
Cite
CITATION STYLE
APA
Brammer, J. E. (2018, February 22). Dual PI3K blockade: PTCL’s Achilles heel? Blood. American Society of Hematology. https://doi.org/10.1182/blood-2017-12-820258
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free